Back to today’s briefing

Story perspectives

EU Agency Investigates Semaglutide Over Eye Condition Risk

1/18/2025

46 8

Summary

Story summary

The European Medicines Agency's safety committee is investigating semaglutide after studies revealed a troubling rise in non-arteritic anterior ischemic optic neuropathy (NAION) among users. This rare eye condition has raised alarms, prompting a thorough review of clinical data and literature to ensure patient safety in diabetes and obesity treatments.

1 of 1

Story summary

The European Medicines Agency's safety committee is investigating semaglutide after studies revealed a troubling rise in non-arteritic anterior ischemic optic neuropathy (NAION) among users. This rare eye condition has raised alarms, prompting a thorough review of clinical data and literature to ensure patient safety in diabetes and obesity treatments.